HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

diroximel fumarate

Also Known As:

vumerity

Networked: 27 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Dicarboxylic Acids: 108
      - Fumarates: 813
        diroximel fumarate: 27

Experts

1.	Miller, Catherine: 5 articles (06/2021 - 11/2019)
2.	Chen, Hailu: 4 articles (01/2022 - 01/2020)
3.	Naismith, Robert T: 4 articles (01/2022 - 01/2020)
4.	Wundes, Annette: 4 articles (01/2022 - 01/2020)
5.	Hanna, Jerome: 4 articles (01/2021 - 11/2019)
6.	Gudesblatt, Mark: 3 articles (01/2022 - 11/2020)
7.	Jasinska, Elzbieta: 3 articles (01/2022 - 01/2020)
8.	Lyons, Jennifer: 3 articles (01/2022 - 01/2020)
9.	Shankar, Sai L: 3 articles (01/2022 - 06/2021)
10.	Singer, Barry A: 3 articles (01/2022 - 01/2021)

Related Diseases

1.	Relapsing-Remitting Multiple Sclerosis 12/01/2023 - "Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study." 11/01/2020 - "Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study." 12/01/2023 - "Diroximel fumarate (DRF) is approved for adults with relapsing-remitting multiple sclerosis (RRMS) in Europe and for relapsing forms of MS in the United States. " 06/01/2023 - "Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate." 01/01/2020 - "Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study."
2.	Multiple Sclerosis 12/01/2023 - "Response to Letter to the Editor Regarding "Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis"." 12/01/2023 - "Letter to the Editor Regarding: "Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis"." 02/01/2023 - "Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis." 10/01/2022 - "Diroximel fumarate for multiple sclerosis." 01/01/2022 - "Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews."
3.	COVID-19 01/01/2021 - "In the Biogen Global Safety Database, we identified 1217 patients who were COVID-19 positive treated with intramuscular interferon beta-1a, peginterferon beta-1a, natalizumab, dimethyl fumarate, diroximel fumarate, or fampridine. " 04/01/2022 - "We systematically reviewed charts and queried patients during clinic encounters in the NYU MS Comprehensive Care Center (MSCCC) for evidence of COVID-19 in all patients who were on the most commonly used DMTs in our clinic (sphingosine-1-phosphate receptor (S1P) modulators (fingolimod/siponimod), rituximab, ocrelizumab, fumarates (dimethyl fumarate/diroximel fumarate), and natalizumab). "
4.	Herpes Zoster 06/01/2023 - "Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate."

Related Drugs and Biologics

1.	Dimethyl Fumarate
2.	Fumarates
3.	Natalizumab (Tysabri)
4.	monomethyl fumarate
5.	ocrelizumab
6.	Interferon-beta
7.	COVID-19 Vaccines
8.	Sphingosine-1-Phosphate Receptors
9.	Rituximab (Mabthera)
10.	Fingolimod Hydrochloride (FTY720)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration